Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric).
Publication
, Conference
Khasraw, M; McCowatt, SA; Kerestes, Z; Buyse, ME; Back, M; Wheeler, H
Published in: Journal of Clinical Oncology
May 20, 2011
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2011
Volume
29
Issue
15_suppl
Start / End Page
TPS133 / TPS133
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Khasraw, M., McCowatt, S. A., Kerestes, Z., Buyse, M. E., Back, M., & Wheeler, H. (2011). Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric). In Journal of Clinical Oncology (Vol. 29, pp. TPS133–TPS133). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2011.29.15_suppl.tps133
Khasraw, M., S. A. McCowatt, Z. Kerestes, M. E. Buyse, M. Back, and H. Wheeler. “Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric).” In Journal of Clinical Oncology, 29:TPS133–TPS133. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.tps133.
Khasraw M, McCowatt SA, Kerestes Z, Buyse ME, Back M, Wheeler H. Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011. p. TPS133–TPS133.
Khasraw, M., et al. “Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric).” Journal of Clinical Oncology, vol. 29, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2011, pp. TPS133–TPS133. Crossref, doi:10.1200/jco.2011.29.15_suppl.tps133.
Khasraw M, McCowatt SA, Kerestes Z, Buyse ME, Back M, Wheeler H. Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011. p. TPS133–TPS133.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2011
Volume
29
Issue
15_suppl
Start / End Page
TPS133 / TPS133
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences